Most people with diabetes are prescribed glucose‐lowering medication to achieve adequate glucose control.2 In 2016, antidiabetes drugs were identified as the section of National Health Service (NHS) prescribing with the greatest spend.3 In 2016 to 2017, 11.0% of England's total primary care net ingredient costs (NICs) were spent on diabetes, costing £984 m.4 While 54.9% of this was spent on insulin and diagnostic/monitoring items, the remaining £444 m went on the subset of “other antidiabetic drugs” (paragraph 6.1.2 of the British National Formulary [BNF]). The gene discussed is INS; the disease is diabetes mellitus.